The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.

Additionally, patients administered with PBF-680 showed statistically significant improvement compared to placebo treated patients in most of the secondary endpoints evaluated, including FEV1 AUC on day 15 and the Asthma Control Questionnaire.

Remarkably, PBF-680 treatment caused a robust decrease in eosinophil counts at day 15, which recover to normal values two weeks later.

No serious adverse events were reported in the trial, demonstrating once again the very good safety and tolerability profile of the compound.

Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

A chip against chronic bacterial infecti...

by IBEC - Institut de Bioenginyeria de Catalunya

IBEC researchers develop a device that allows to grow biofilms and ana...

Photos Stream